JP2023509441A5 - - Google Patents
Info
- Publication number
- JP2023509441A5 JP2023509441A5 JP2022540904A JP2022540904A JP2023509441A5 JP 2023509441 A5 JP2023509441 A5 JP 2023509441A5 JP 2022540904 A JP2022540904 A JP 2022540904A JP 2022540904 A JP2022540904 A JP 2022540904A JP 2023509441 A5 JP2023509441 A5 JP 2023509441A5
- Authority
- JP
- Japan
- Prior art keywords
- drawings
- invention described
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962955847P | 2019-12-31 | 2019-12-31 | |
| US62/955,847 | 2019-12-31 | ||
| US202063066717P | 2020-08-17 | 2020-08-17 | |
| US63/066,717 | 2020-08-17 | ||
| US202063086442P | 2020-10-01 | 2020-10-01 | |
| US202063086275P | 2020-10-01 | 2020-10-01 | |
| US63/086,275 | 2020-10-01 | ||
| US63/086,442 | 2020-10-01 | ||
| PCT/US2020/067612 WO2021138525A1 (en) | 2019-12-31 | 2020-12-31 | Topical composition comprising tofacitinib and fingolimod |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023509441A JP2023509441A (ja) | 2023-03-08 |
| JP2023509441A5 true JP2023509441A5 (cg-RX-API-DMAC7.html) | 2024-01-17 |
Family
ID=74285586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022540904A Pending JP2023509441A (ja) | 2019-12-31 | 2020-12-31 | トファシチニブおよびフィンゴリモドを含む局所組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230037905A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4084776A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023509441A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020417290A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022012917A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3163530A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL294239A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202135825A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021138525A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010302350B2 (en) | 2009-10-02 | 2015-06-18 | Journey Medical Corporation | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
| US12661407B2 (en) | 2010-04-08 | 2026-06-23 | Journey Medical Corporation | Compositions, gels and foams with rheology modulators and uses thereof |
| JP7324210B2 (ja) * | 2018-01-31 | 2023-08-09 | ティダブリューアイ・バイオテクノロジー・インコーポレイテッド | トファシチニブを含む局所製剤 |
| CN116437921A (zh) * | 2020-09-28 | 2023-07-14 | 株式会社Lg化学 | 鞘氨醇-1-磷酸酯受体激动剂的用途 |
| CN120168480A (zh) * | 2025-04-17 | 2025-06-20 | 四川省医学科学院·四川省人民医院 | 托法替尼在制备治疗干性年龄相关性黄斑变性的药物中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4874794A (en) | 1989-04-28 | 1989-10-17 | Lidak Biopharmaceuticals | Inflammatory disease treatment |
| US9474720B2 (en) | 2013-11-04 | 2016-10-25 | BioPharmX, Inc. | Dosage form comprising an active ingredient and a plurality of solid porous microcarriers |
-
2020
- 2020-12-31 AU AU2020417290A patent/AU2020417290A1/en not_active Abandoned
- 2020-12-31 US US17/758,175 patent/US20230037905A1/en not_active Abandoned
- 2020-12-31 TW TW109147197A patent/TW202135825A/zh unknown
- 2020-12-31 WO PCT/US2020/067612 patent/WO2021138525A1/en not_active Ceased
- 2020-12-31 BR BR112022012917A patent/BR112022012917A2/pt not_active Application Discontinuation
- 2020-12-31 JP JP2022540904A patent/JP2023509441A/ja active Pending
- 2020-12-31 EP EP20845858.8A patent/EP4084776A1/en not_active Withdrawn
- 2020-12-31 CA CA3163530A patent/CA3163530A1/en active Pending
- 2020-12-31 IL IL294239A patent/IL294239A/en unknown